Van Morris, Section Chief of Colorectal Cancer and Associate Professor at MD Anderson Cancer Center, shared a post on X:
“Does chemotherapy affect the biology of BRAF V600E mCRC when combined with encorafenib + ceruximab?
Answer appears to be YES! Very intriguing translational finding showing that addition of chemo to E+C reduces development of acquired RAS, MAP2K1 , and other mutations that drive resistance to BRAF + EGFR blockade.
Will use this data in counseling patients why we add chemo to E+C in this pt population.
Applause to BREAKWATER team for releasing translational data on their large 500 pt analysis!! And congrats to the always amazing skopetz for an incredible presentation- our MD Anderson News team remains so inspired by you!!”
You Can Also Read:
ESMO 2025 Day 1 Highlights Not to Miss
ESMO 2025 Day 2 Highlights Not to Miss
ESMO 2025 Day 3 Highlights Not to Miss
